{"brief_title": "Rotavirus Efficacy and Safety Trial (REST)(V260-006)", "brief_summary": "This study was designed to evaluate the safety of the investigational rotavirus vaccine and the efficacy to prevent rotavirus gastroenteritis.", "condition": ["Rotavirus Infections"], "intervention_type": ["Biological", "Biological"], "intervention_name": ["Rotateq\u2122", "Comparator: Placebo"], "description": ["3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.", "3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2."], "arm_group_label": ["1", "2"], "other_name": ["V260"], "criteria": "Inclusion Criteria: - Healthy infants Exclusion Criteria: - None Specified", "gender": "All", "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "healthy_volunteers": "Accepts Healthy Volunteers", "mesh_term": ["Rotavirus Infections"], "id": "NCT00090233"}